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Summary
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to 
hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide 
reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of 
complications in the community.
Methods PRINCIPLE is a multicentre, open-label, multi-arm, randomised, controlled, adaptive platform trial done 
remotely from a central trial site and at primary care centres in the UK. Eligible participants were aged 65 years or 
older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted 
to hospital. Participants were randomly assigned to usual care, usual care plus inhaled budesonide (800 µg twice daily 
for 14 days), or usual care plus other interventions, and followed up for 28 days. Participants were aware of group 
assignment. The coprimary endpoints are time to first self-reported recovery and hospital admission or death related 
to COVID-19, within 28 days, analysed using Bayesian models. The primary analysis population included all eligible 
SARS-CoV-2-positive participants randomly assigned to budesonide, usual care, and other interventions, from the 
start of the platform trial until the budesonide group was closed. This trial is registered at the ISRCTN registry 
(ISRCTN86534580) and is ongoing.
Findings The trial began enrolment on April 2, 2020, with randomisation to budesonide from Nov 27, 2020, until 
March 31, 2021, when the prespecified time to recovery superiority criterion was met. 4700 participants were randomly 
assigned to budesonide (n=1073), usual care alone (n=1988), or other treatments (n=1639). The primary analysis 
model includes 2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care 
group, and 974 receiving other treatments. There was a benefit in time to first self-reported recovery of an estimated 
2·94 days (95% Bayesian credible interval [BCI] 1·19 to 5·12) in the budesonide group versus the usual care group 
(11·8 days [95% BCI 10·0 to 14·1] vs 14·7 days [12·3 to 18·0]; hazard ratio 1·21 [95% BCI 1·08 to 1·36]), with a 
probability of superiority greater than 0·999, meeting the prespecified superiority threshold of 0·99. For the hospital 
admission or death outcome, the estimated rate was 6·8% (95% BCI 4·1 to 10·2) in the budesonide group versus 8·8% 
(5·5 to 12·7) in the usual care group (estimated absolute difference 2·0% [95% BCI –0·2 to 4·5]; odds ratio 0·75 
[95% BCI 0·55 to 1·03]), with a probability of superiority 0·963, below the prespecified superiority threshold of 0·975. 
Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital 
admissions unrelated to COVID-19).
Interpretation Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or 
deaths (although our results did not meet the superiority threshold), in people with COVID-19 in the community 
who are at higher risk of complications.
Funding National Institute of Health Research and United Kingdom Research Innovation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
There is an urgent need for effective and safe community-
based treatments for COVID-19, especially for older 
people and those with comorbidities who are at higher 
risk of hospital admission and death.1
Inhaled corticosteroids are widely available, inexpen-
sive, and generally safe, and have been proposed as a 
COVID-19 treatment because of their targeted anti-
inflammatory effects in the lungs,2,3 where they also 
reduce expression of ACE-2 and TMPRSS2,4,5 which is 
relevant for airway epithelial cell entry by SARS-CoV-2.6 
Inhaled steroids also reduce replication of SARS-CoV-2 in 
epithelial cells in vitro.7 Early in the COVID-19 pandemic, 
the low prevalence of asthma and chronic obstructive 
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pulmonary dis ease among people admitted to hospital 
with COVID-19 led to speculation that the inhaled 
corticosteroids used to treat these conditions might be 
protective.2,3 Furthermore, systemic corticosteroids reduce 
deaths in patients admitted to hospital with COVID-19,8,9 
probably because the hyperinflammatory state is 
responsible for the subsequent damage from SARS-CoV-2 
infection.10 However, subgroup analyses in the 
RECOVERY trial suggested no benefit, and possible 
harm, with use of systemic corticosteroids in patients 
admitted to hospital not requiring oxygen.8 In addition, 
observational, population-based studies in primary care 
in the UK found an increased risk of COVID-19 hospital 
admission or death among people prescribed inhaled 
cortico steroids for chronic lung disease,11,12 although 
residual confounding by unmeasured disease severity 
could not be ruled out. An efficacy trial of adults with 
early COVID-19 in the community found inhaled 
budesonide reduced COVID-19-related emergency 
assessments or hospital admissions, and time to self-
reported recovery.13 However, thus far, there are no results 
reported from large effectiveness trials of inhaled 
budesonide for COVID-19.
We therefore aimed to establish the effectiveness of 
inhaled budesonide in reducing recovery time and rates 
of COVID-19-related hospital admission or death in 




PRINCIPLE is a multicentre, open-label, multi-arm, 
prospective, randomised, controlled, adaptive platform 
trial of interventions against COVID-19 in people aged 
65 years or older or 50 years or older with comorbidities, 
done remotely from a central trial site and at primary 
care centres in the UK. The protocol is available in the 
appendix (pp 4–80) and on the trial website. A platform 
trial allows multiple treatments for the same disease to 
be assessed simultaneously. A master protocol defines 
prospective decision criteria for dropping inter ventions 
for futility, declaring interventions superior, or adding 
new interventions.14 The interventions assessed in 
PRINCIPLE were hydroxychloroquine, azithromycin,15 
doxycycline,16 colchicine, favipiravir and, reported here, 
inhaled budesonide.
The UK Medicines and Healthcare products Regulatory 
Agency and the South Central-Berkshire Research Ethics 
Committee (ref 20/SC/0158) approved the trial protocol. 
Online consent was obtained from all participants before 
enrolment.
Participants
People in the community were eligible if they were aged 
at least 65 years, or at least 50 years with comorbidities, 
and had ongoing symptoms from PCR-confirmed or 
suspected COVID-19 (in accordance with the UK National 
N P B Thomas PhD); Royal 
College of General 
Practitioners, London, UK 
(N P B Thomas); National Heart 
and Lung Institute, Imperial 
College, London, UK 
(Prof P J Barnes FRS); UQ Centre 
for Clinical Research, University 
of Queensland, Brisbane, QLD, 
Australia (D V Nicolau Jr); 
National Institute for Health 
Research Oxford Biomedical 
Research Centre, Oxford, UK 
(S Ramakrishnan MBBS)
Correspondence to: 
Prof Christopher C Butler, 
Nuffield Department of Primary 
Care Health Sciences, University 




Prof F D Richard Hobbs, Nuffield 
Department of Primary Care 
Health Sciences, University of 
Oxford, Oxford OX2 6GG, UK 
richard.hobbs@phc.ox.ac.uk
See Online for appendix
Research in context
Evidence before this study
We did a search of PubMed on June 24, 2021, using the 
following search terms “(randomised OR trial) AND 
(budesonide OR inhaled corticosteroids OR inhaled steroids) 
AND (COVID* OR SARS-CoV-2 OR SARS-CoV)”, with no date or 
language restrictions. The search identified 44 results, 
one of which reported findings from a randomised controlled 
trial. In the STOIC phase 2, open-label trial, among adults aged 
18 years and older with early, suspected COVID-19 in the 
community, 146 participants were randomly assigned to 
inhaled budesonide 800 µg twice a day until symptoms 
resolved, or usual care. The primary outcome of COVID-19-
related urgent care or emergency department assessment, 
or hospital admission, was achieved in one (1%) of 
70 participants receiving budesonide versus ten (14%) of 
69 receiving usual care (difference in proportions 0·131 [95% CI 
0·043–0·218], p=0·004). Secondary outcomes in STOIC also 
favoured budesonide over usual care with respect to time to 
self-reported recovery, symptom persistence at day 14, 
and resolution of fever. A search of ClinicalTrials.gov on 
June 24, 2021, using the terms “COVID-19” and “ciclesonide” 
OR “mometasone” OR “fluticasone” OR “beclometasone” OR 
“budesonide”, identified ten additional ongoing or completed 
randomised controlled trials assessing budesonide as treatment 
for COVID-19 studies, none of which had reported results.
Added value of this study
To our knowledge, PRINCIPLE is the first pragmatic 
randomised trial to report the effectiveness of an inhaled 
corticosteroid for people with COVID-19 in the community. 
We found that inhaled budesonide reduced time to recovery 
by 3 days, with a high probability of also reducing COVID-19-
related hospital admissions or deaths by an absolute 
difference of 2%.
Implications of all the available evidence
PRINCIPLE is the first randomised trial to demonstrate 
effectiveness of inhaled budesonide to treat COVID-19 in the 
community, and builds on earlier evidence from the phase 2 
STOIC trial. Reducing time to recovery is an important 
outcome for patients, whereas potential prevention of 
hospital admissions or deaths would lessen the burden on 
hospitals during COVID-19 surges. There was no evidence in 
the STOIC trial of a negative effect of budesonide on 
SARS-CoV-2 viral loads, and in PRINCIPLE there were no 
concerning safety signals for inhaled budesonide. Inhaled 
budesonide should be considered for patients with COVID-19 
who are at higher risk of complications in the community.
For the PRINCIPLE trial website 
see www.principletrial.org
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Health Service definition of high temperature, new, 
continuous cough, or change in sense of smell or 
taste),17,18 which had started within the previous 14 days. 
Comorbidities required for eligibility in those aged 
50–65 years were heart disease, hypertension, asthma or 
lung disease, diabetes, hepatic impairment, stroke or 
neurological problems, weakened immune system (eg, 
receiving chemotherapy), and self-reported obesity or 
body-mass index of at least 35 kg/m². People were 
ineligible to be assigned to budesonide if they were 
already taking inhaled or systemic cortico steroids, 
were unable to use an inhaler, or if inhaled budesonide 
was contraindicated according to the British National 
Formulary. Initially, eligible people were recruited, 
screened, and enrolled through participating general 
medical practices, but from May 17, 2020, people across 
the UK could enrol online or by telephone. After patients 
completed a baseline and screening ques tionnaire, a 
clinician or trained research nurse confirmed eligibility 
using the patient’s primary care medical record, accessed 
remotely where necessary, before conducting random-
isation. To increase recruitment from ethnic minority 
and socially deprived communities, which have been 
disproportionally affected by COVID-19, we used several 
outreach strategies, including the appointment in 
September, 2020, of an expert working with ethnic 
minority groups; active collaborations with community, 
religious, and health organisations; and promotion in 
multiple languages through a range of media.19
Randomisation and masking
Eligible, consenting participants were randomly assigned 
using a secure, in-house, web-based randomisation 
system (Sortition version 2.3) to budesonide, usual care, 
or other treatments. Randomisation probabilities were 
established using response-adaptive randomisation via 
regular interim analyses, which allows allocation of 
more participants to interventions with better observed 
time-to-recovery outcomes (appendix pp 140–142). 
Between Dec 14, 2020, and March 4, 2021, when only the 
budesonide and usual care groups were open, there was 
1:1 allocation between each, stratified by age (<65 years vs 
≥65 years), and presence of comorbidity (yes vs no). The 
trial team was masked to randomisation probabilities, 
but all participants were aware of group assignment.
Procedures
Participants received usual care plus inhaled budesonide 
800 µg twice daily for 14 days (Pulmicort Turbohaler, 
AstraZeneca, Luton, UK), or usual care alone. The 
breath-actuated inhaler was chosen because of its ease 
of use, and was either prescribed or issued directly by 
the participant’s general medical practitioner, or issued 
centrally by the study team and delivered to the 
participant by urgent courier. Participants in the 
budesonide group were sent a video link demonstrating 
inhaler use, with additional telephone support where 
necessary. Usual care in the UK National Health Service 
for suspected COVID-19 in the community is largely 
focused on managing symptoms with antipyretics, with 
antibiotics only recommended if bacterial pneumonia is 
suspected.20,21
Participants were followed up through an online, 
daily symptom diary for 28 days after randomisation, 
supplemented with telephone calls to non-responders 
on days 7, 14, and 28. The diary includes questions 
about illness recovery (ascertained by answering the 
question, “Do you feel recovered today? (ie, symptoms 
associated with illness are no longer a problem) 
yes vs no”), overall illness severity (a rating of how well 
they are feeling on a scale of 1–10, 1 being the worst and 
10 being the best), individual symptom severity on a 
four point scale (0 being no problem to 3 being major 
problem), and health-care service use. Participants 
could nominate a trial partner to help provide follow-up 
data. We obtained consent to ascertain health-care use 
outcome data from general practice and hospital 
records. We aimed to provide a self-swab for SARS-
CoV-2 confirmatory PCR testing, but capacity issues 
early in the pandemic meant testing was unavailable 
for some participants.
Outcomes
The trial commenced with the primary outcome of 
COVID-19-related hospital admission or death within 
28 days. However, hospital admission rates in the UK22 
were lower than initially expected.23 Therefore, the 
trial management group and trial steering committee 
recommended amending the primary outcome to also 
include illness duration,24,25 which is an important 
outcome for patients and has substantial economic 
and social impacts. This received ethical approval on 
Sept 16, 2020, and was implemented before performing 
any interim analyses. Thus, the trial has two coprimary 
endpoints measured within 28 days of randomisation: 
time to first reported recovery defined as the first 
instance that a participant reports feeling recovered; 
and hospital admission or death related to COVID-19. 
Decisions about COVID-19 relatedness were made after 
independent review of available data by two clinicians 
masked to treatment allocation and study identifiers.
Secondary outcomes (defined in section 3.3 of the 
master statistical analysis plan; appendix pp 102–109) 
include a binary outcome of early, sustained recovery 
(recovered by day 14 and remains recovered until day 28), 
time to sustained recovery (date participant first reports 
recovery and subsequently remains well until 28 days), 
daily rating of 1–10 of how well participants feel, time to 
initial alleviation of symptoms (date symptoms first 
reported as minor or none), time to sustained alleviation 
of symptoms (date symptoms first reported as minor or 
none and subsequently remain minor or none until 
28 days), time to initial reduction of severity of symptoms 
(date symptom severity reported at least one grade 
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lower), contacts with health services, hospital assessment 
without admission, oxygen admin istration, intensive 
care unit admission, mechanical ventilation, adherence 
to study treatment, WHO-5 Well-Being Index,26 and 
reports of new household infections. All time-to-event 
analyses used date of randomisation as baseline. We 
included secondary outcomes that capture sustained 
recovery because of the often recurrent and relapsing 
nature of COVID-19 symptoms. Serious adverse events 
other than the coprimary outcome of hospital admission 
or death related to COVID-19 were measured in all trial 
groups.
Figure 1: Trial profile
GP=general practitioner. *Participants provided no diary information. †Analysis for secondary outcomes.
4700 randomised
4720 enrolled
18 aged <50 years
2 aged <65 years and no comorbidity
6378 registered for GP eligibility check
38 520 patients screened for eligibility
 
32 142 not eligible
1639 allocated to other treatments1988 allocated to usual care
1959 received usual care 
(1126 SARS-CoV-2-positive,
833 SARS-CoV-2 negative, unknown,
or not tested)
8 ineligible
21 withdrew consent and no medical 
notes review*
1073 allocated to inhaled budesonide
 
1047 received assigned treatment 
(833 SARS-CoV-2 positive,
214 SARS-CoV-2 negative, unknown, 
or not tested)
16 ineligible
10 withdrew consent and no 
medical notes review*
1529 in all participants population for 
primary analysis
6 recovered at day 0
77 no diary information
27 other reasons
1858 in all participants population for 
primary analysis
12 recovered at day 0
89 no diary information
 
990 in all participants population for 
primary analysis
 
3 recovered at day 0
54 no diary information
674 in SARS-CoV-2-positive analysis 
population for primary analysis
 181 in concurrent randomisation 
SARS-CoV-2-positive population
 
855 SARS-CoV-2 negative, unknown, 
or not tested
1069 in SARS-CoV-2-positive analysis 
population for primary analysis
 838 in concurrent randomisation 
SARS-CoV-2-positive population
 799 in concurrent randomisation and 
budesonide-eligible SARS-CoV-2-
positive population†
789 SARS-CoV-2 negative, unknown, 
or not tested
 
787 in SARS-CoV-2-positive analysis 
population for primary analysis
 787 in concurrent randomisation 
SARS-CoV-2-positive population
 787 in concurrent randomisation and 
budesonide-eligible SARS-CoV-2-
positive population†




 18 could not be contacted
 217 no response from participants
 80 no response from GP
 144 no consent or no baseline form
 27 no longer wish to take part
 17 not registered with GP
 10 GP refused
 12 eligibility check in progress
 3 reasons unknown
Articles
www.thelancet.com   Published online August 10, 2021   https://doi.org/10.1016/S0140-6736(21)01744-X 5








Usual care  
(n=886)
Age
Mean (SD), years 64·7 (7·3) 63·8 (7·8) 64·7 (7·3) 64·5 (7·7)
50–64 years 297 (36%) 475 (42%) 297 (36%) 322 (36%)
≥65 years 536 (64%) 651 (58%) 536 (64%) 564 (64%)
Sex
Female 429 (52%) 586 (52%) 429 (51%) 455 (51%)
Male 404 (48%) 540 (48%) 404 (48%) 431 (49%)
Ethnicity†
White 767 (92%) 1038 (92%) 767 (92%) 820 (93%)
Mixed 9 (1%) 5 (<1%) 9 (1%) 4 (<1%)
South Asian 43 (5%) 64 (6%) 43 (5%) 48 (5%)
Black 6 (1%) 4 (<1%) 6 (1%) 3 (<1%)
Other 8 (1%) 14 (1%) 8 (1%) 11 (1%)
Missing 0 1 (<1%) 0 0
Index of multiple deprivation quintile
1 (most deprived) 140 (17%) 196 (17%) 140 (17%) 149 (17%)
2 157 (19%) 187 (17%) 157 (19%) 156 (18%)
3 164 (20%) 227 (20%) 164 (20%) 180 (20%)
4 180 (22%) 252 (22%) 180 (22%) 202 (23%)
5 (least deprived) 190 (23%) 264 (23%) 190 (23%) 199 (22%)
Missing 2 (<1%) 0 2 (<1%) 0
Duration of illness before randomisation, days 6·0 (4·0–9·0) 6·0 (4·0–9·0) 6·0 (4·0–9·0) 6·0 (4·0–9·0)
Smoking status
Current smoker 44 (5%) 60 (5%) 44 (5%) 45 (5%)
Former smoker 342 (41%) 460 (41%) 342 (41%) 363 (41%)
Never smoker 440 (53%) 592 (53%) 440 (53%) 468 (53%)
Missing 7 (1%) 14 (1%) 7 (1%) 10 (1%)
Received SARS-CoV-2 vaccination 111 (13%) 108 (10%) 111 (13%) 108 (12%)
Vaccine doses received
One dose 105 (13%) 100 (9%) 105 (13%) 100 (11%)
Two doses 6 (1%) 8 (1%) 6 (1%) 8 (1%)
Comorbidity 665 (80%) 916 (81%) 665 (80%) 705 (80%)
Number of comorbidities 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
Comorbidities
Asthma, chronic obstructive pulmonary disease, 
or lung disease
72 (9%) 174 (15%) 72 (9%) 96 (11%)
Diabetes 169 (20%) 251 (22%) 169 (20%) 200 (23%)
Heart problems‡ 139 (17%) 171 (15%) 139 (17%) 134 (15%)
High blood pressure requiring medication 382 (46%) 486 (43%) 382 (46%) 388 (44%)
Liver disease 17 (2%) 22 (2%) 17 (2%) 20 (2%)
Stroke or other neurological problem 51 (6%) 59 (5%) 51 (6%) 43 (5%)
Taking angiotensin-converting enzyme inhibitor§ 199 (24%) 235 (21%) 199 (24%) 185 (21%)
Missing 3 (<1%) 6 (1%) 3 (<1%) 3 (<1%)
Fever
No problem 414 (50%) 524 (47%) 414 (50%) 413 (47%)
Mild problem 242 (29%) 359 (32%) 242 (29%) 290 (33%)
Moderate problem 152 (18%) 207 (18%) 152 (18%) 153 (17%)
Major problem 25 (3%) 36 (3%) 25 (3%) 30 (3%)
(Table 1 continues on next page)
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Usual care  
(n=886)
(Continued from previous page)
Cough
No problem 138 (17%) 186 (17%) 138 (16%) 134 (15%)
Mild problem 366 (44%) 499 (44%) 366 (44%) 382 (43%)
Moderate problem 264 (32%) 373 (33%) 264 (32%) 309 (35%)
Major problem 65 (8%) 68 (6%) 65 (8%) 61 (7%)
Shortness of breath
No problem 409 (49%) 522 (46%) 409 (49%) 428 (48%)
Mild problem 282 (34%) 420 (37%) 282 (34%) 313 (35%)
Moderate problem 121 (15%) 165 (15%) 121 (14%) 127 (14%)
Major problem 21 (3%) 19 (2%) 21 (3%) 18 (2%)
Muscle ache
No problem 217 (26%) 262 (23%) 217 (26%) 202 (23%)
Mild problem 263 (32%) 412 (37%) 263 (32%) 326 (37%)
Moderate problem 246 (30%) 340 (30%) 246 (29%) 265 (30%)
Major problem 107 (13%) 112 (10%) 107 (13%) 93 (10%)
Nausea or vomiting
No problem 572 (69%) 771 (68%) 572 (69%) 595 (67%)
Mild problem 160 (19%) 239 (21%) 160 (19%) 191 (22%)
Moderate problem 79 (9%) 88 (8%) 79 (9%) 76 (9%)
Major problem 22 (3%) 28 (2%) 22 (3%) 24 (3%)
Feeling generally unwell
No problem 28 (3%) 46 (4%) 28 (3%) 31 (3%)
Mild problem 293 (35%) 380 (34%) 293 (35%) 291 (33%)
Moderate problem 369 (44%) 507 (45%) 369 (44%) 393 (44%)
Major problem 143 (17%) 183 (16%) 143 (17%) 171 (19%)
Missing 0 10 (1%) 0 0
Diarrhoea
No problem 614 (74%) 822 (73%) 614 (74%) 655 (74%)
Mild problem 137 (16%) 200 (18%) 137 (16%) 152 (17%)
Moderate problem 65 (8%) 68 (6%) 65 (8%) 57 (6%)
Major problem 17 (2%) 26 (2%) 17 (2%) 22 (2%)
Missing 0 10 (1%) 0 0
Taken antibiotics since illness started 61 (7%) 77 (7%) 61 (7%) 70 (8%)
Missing 0 1 (<1%) 0 0
Use of health-care services
General practitioner 212 (25%) 290 (26%) 212 (25%) 219 (25%)
Other primary care services 91 (11%) 96 (9%) 91 (11%) 88 (10%)
NHS 111 93 (11%) 125 (11%) 93 (11%) 94 (11%)
Accident and emergency 17 (2%) 19 (2%) 17 (2%) 15 (2%)
Other 25 (3%) 30 (3%) 25 (3%) 25 (3%)
WHO-5 Well-Being Index¶ 45·7 (25·3) 46·1 (26·1) 45·7 (25·3) 45·1 (26·3)
Missing 0 2 (<1%) 0 0
Data are n (%), median (IQR), or mean (SD). *Includes participants assigned before the inhaled budesonide group was open. †Data on ethnicity were collected retrospectively 
via notes review before July, 2020. ‡Includes angina, heart attack, heart failure, atrial fibrillation, and valve problems. §Includes ramipril, lisinopril, perindopril, captopril, 
or enalapril. ¶Includes five items relating to wellbeing measured on a five-point scale; a total score is computed by summing the scores to the five individual questions to give 
a raw score of 0–25, which is then multiplied by 4 to give the final score from 0, representing the worst imaginable wellbeing, to 100, representing the best imaginable 
wellbeing.
Table 1: Baseline characteristics of SARS-CoV-2-positive participants by treatment group
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Statistical analysis
Sample size calculation and statistical analysis are 
detailed in the adaptive design report (appendix 
pp 130–230) and the master statistical analysis plan 
(appendix pp 81–129). In the adaptive design report, 
we justify sample sizes by simulating the operating 
characteristics of the adaptive design in multiple 
scenarios, which explicitly account for response-
adaptive randomisation, early stopping for futility or 
success, and multiple interventions. Briefly, for the 
primary outcome analyses, assuming a median time to 
recovery of 9 days in the usual care group, about 
400 participants per group would provide 90% power to 
detect a 2-day difference in median recovery time. 
Assuming 5% hospital admission in the usual care 
group, about 1500 participants per group would provide 
90% power to detect a 50% reduction in the relative risk 
of hospital admission or death.
The first coprimary outcome, time to first self-reported 
recovery, was analysed using a Bayesian piecewise 
exponential model. The second coprimary outcome, 
hospital admission or death, was analysed using a 
Bayesian logistic regression model. Both models were 
regressed on treatment group and stratification 
covariates (age <65 years vs ≥65 years and comorbidity 
yes vs no). These primary outcomes were assessed using 
a gate-keeping strategy to preserve the overall type I 
error without additional adjustments for multiple 
hypotheses. The hypothesis for the time to first recovery 
endpoint was assessed first, and if the null hypothesis 
was rejected, the hypothesis for the second coprimary 
endpoint of hospital admission or death was assessed. 
In the context of multiple interim analyses, the master 
protocol specifies that each null hypothesis is rejected 
if the Bayesian posterior probability of superiority 
exceeded 0·99 for the time to recovery endpoint 
and 0·975 (via gate keeping) for the hospital admission 
or death endpoint.
At the beginning of the trial, because of initial 
difficulties with community SARS-CoV-2 PCR testing in 
the UK, participants with suspected COVID-19 were 
included in the primary analysis population, irrespective 
of confirmatory testing. When testing became more 
accessible, the trial steering committee recommended 
restricting the primary analysis population to those with 
confirmed COVID-19. This change was included in 
protocol, version 7.1, on Feb 22, 2021, and approved on 
March 15, 2021, before any interim budesonide results 
were disclosed to the trial management group. There-
fore, the prespecified primary analysis population 
includes all eligible SARS-CoV-2-positive participants 
randomly assigned to budesonide, usual care, and other 
interventions, from the start of the platform trial until 
the budesonide group was closed, on March 31, 2021. 
This population includes participants randomly assigned 
to usual care before the budesonide group opened, who 
might differ from concurrently assigned participants 
because of changes in the inclusion or exclusion 
criteria (eg, current inhaled corticosteroid use was only 
added as an exclusion criterion when the budesonide 
group opened), and changes over time in circulating 
SARS-CoV-2 or usual care, including increasing avail-
ability of vaccinations. Therefore, the primary analysis 
models include parameters to adjust for this temporal 
drift in the trial population, by estimating the primary 
endpoint in the usual care group across time via 
Bayesian hierarchical modelling. We also accounted for 
potential temporal drift by conducting a prespecified 
sensitivity analysis of the primary outcomes using 
the concurrent assigned population; defined as all 
SARS-CoV-2-positive participants randomly assigned 
during the time period when the budesonide group was 
Figure 2: Time to first reported recovery
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active. To establish the applicability of our results to 
situations where PCR testing might not be readily 
available, we also did secondary analyses of time to 
recovery and COVID-19-related hospital admission or 
death among the overall study population, irrespective 
of SARS-CoV-2 status.
Analysis of all secondary outcomes and prespecified 
subgroup analyses were done in SARS-CoV-2-positive 
participants eligible for budesonide and concurrently 
assigned to budesonide or usual care—the concurrent 
randomisation and eligible SARS-CoV-2-positive popula-
tion. Secondary time-to-event outcomes were analysed 
using Cox proportional hazard models, and binary 
outcomes were analysed using logistic regression, 
adjusting for comorbidity, age, duration of illness, and 
vaccination status. Because of the high proportion of 
participants contributing to the analysis of primary 
outcomes (95·3%), we did not explore the potential 
impact of missing data. All model assumptions were 
checked and validated.
The primary outcomes were assessed in all partic-
ipants, excluding those who were ineligible, withdrew 
consent, had no diary information, or who recovered 
on day 0. Analyses were done using R (version 3.6.0) 
and Stata (version 16.1). An independent trial steering 
committee and data monitoring and safety committee 
provided trial oversight. The trial is registered at the 
ISRCTN registry (ISRCTN86534580) and is ongoing.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report.
Results
The first participant was randomised into PRINCIPLE 
on April 2, 2020. Enrolment into the budesonide group 
started on Nov 27, 2020. On March 31, 2021, the trial 
steering committee advised the trial management group 
to stop randomisation to budesonide because the 
prespecified superiority criterion had been met on time 
to recovery, and accumulating enough data to reach 
futility or superiority criteria on hospital admission or 
death was unlikely because of decreases in hospital 
admissions associated with the UK lockdown and 
vaccination programme.22
38 520 patients were screened for eligibility, of whom 
4700 were randomly assigned to budesonide (n=1073), 
usual care alone (n=1988), or other treatments (n=1639; 
figure 1). 3979 (87%) of 4594 eligible participants had a 
SARS-CoV-2 test result available, and 2655 (67%) of the 
3979 tested positive. To protect the integrity of 
the platform trial and other interventions, we provide 
descriptive summaries of only those participants 
randomly assigned to budesonide and usual care. In 
SARS-CoV-2-positive participants, the mean age was 
64·2 years (SD 7·6), 1805 (92%) of 1959 participants were 
White, and 1581 (81%) had comorbidities. Median time 
from symptom onset was 6 days (IQR 4–9). Baseline 
characteristics were similar between the treatment 
groups (table 1; appendix pp 237–38). Data on inhaled 
corticosteroid use was only collected once the budesonide 
group opened; 27 (3%) of 886 participants in the 
concurrently randomised usual care group reported 
taking inhaled corticosteroids at randomisation (these 
participants had been randomised between usual care 






median time to recovery 
or hospital admission or 
death rate (95% BCI)






Number of participants 787 1069 ·· ·· ··
Time to first reported recovery, days* 11·8 (10·0 to 14·1) 14·7 (12·3 to 18·0) 2·94 (1·19 to 5·11) 1·21 (1·08 to 1·36) >0·999
Hospital admission or death at 28 days† 6·8% (4·1 to 10·2) 8·8% (5·5 to 12·7) 2·0% (–0·2 to 4·5) 0·75 (0·55 to 1·03) 0·963
Secondary analysis—all participants
Number of participants 990 1858 ·· ·· ··
Time to first reported recovery, days* 10·9 (8·9 to 13·2) 13·3 (11·1 to 16·7) 2·54 (1·00 to 4·54) 1·18 (1·07 to 1·30) >0·999
Hospital admission or death at 28 days† 5·8% (3·4 to 8·6) 7·3% (4·5 to 10·6) 1·5% (–0·3 to 3·6) 0·78 (0·57 to 1·04) 0·953
Sensitivity analysis—concurrent randomisation population
Number of participants 787 838 ·· ·· ··
Time to first reported recovery, days* 11·7 (9·8 to 14·2) 15·0 (12·5 to 18·3) 3·26 (1·46 to 5·43) 1·24 (1·10 to 1·39) >0·999
Hospital admission or death at 28 days† 6·6% (3·8 to 10·1) 8·9% (5·2 to 13·1) 2·2% (0·0 to 4·9) 0·73 (0·53 to 1·00) 0·975
BCI=Bayesian credible interval. *Estimated benefit in median times to recovery are derived from a Bayesian piecewise exponential model adjusted for age and comorbidity at 
baseline, with 95% BCI; a positive value in estimated benefit in median time to recovery (or hazard ratio >1) corresponds to a reduction in time to recovery in days with 
budesonide compared with usual care; treatment superiority is declared if probability of superiority is ≥0·99 versus usual care. †Estimated absolute percentage differences in 
hospital admission or death were derived from a Bayesian logistic regression model adjusted for age and comorbidity at baseline, with 95% BCI; a positive value in the 
estimated percentage difference (or odds ratio <1) favours budesonide; treatment superiority is declared if probability of superiority is ≥0·975 versus usual care.
Table 2: Primary outcomes (model-based estimates)
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for budesonide). Of 969 participants randomly assigned 
to budesonide who provided medication use information, 
772 (80%) reported taking budesonide for at least 7 days.
The Bayesian primary analysis model includes data 
from 2530 (95%) of 2655 SARS-CoV-2-positive par-
ticipants who provided follow-up data and were randomly 
assigned to inhaled budesonide (n=787), usual care 
alone (n=1069), and other treatments (n=674). In the 
primary analysis population, the observed median time to 
first recovery was 11 days (5–not reached) in the inhaled 
budesonide group compared with 15 days (6–not reached) 
in the usual care group (figure 2A). Based on the 
Bayesian primary analysis model, there was evidence of a 
benefit in time-to-first-recovery in the budesonide group 
versus usual care group, with a hazard ratio of 1·21 
(95% Bayesian credible interval [BCI] 1·08–1·36), an 
estimated 11·8 days (95% BCI 10·0–14·1) versus 14·7 days 
(12·3–18·0), and estimated median benefit of 2·94 days 
(95% BCI 1·19–5·11). The probability of superiority was 
greater than 0·999, which met the prespecified superiority 
Inhaled 
budesonide
Usual care Estimated treatment 
effect (95% CI)
p value
Early sustained recovery 251/781 (32%) 173/794 (22%) 1·48 (1·26 to 1·75)* <0·0001
Sustained recovery 462/787 (59%) 390/799 (49%) ·· ··
Time to sustained recovery, days 23 (9 to not 
reached)
28 (15 to not 
reached)
1·39 (1·21 to 1·59)† <0·0001
Alleviation of all symptoms 630/701 (90%) 666/732 (91%) ·· ··
Time to alleviation of all symptoms, days 4 (2 to 9) 5 (2 to 10) 1·07 (0·96 to 1·19)† 0·26
Sustained alleviation of all symptoms 579/701 (83%) 597/731 (82%) ·· ··
Time to sustained alleviation of all symptoms, days 8 (3 to 24) 12 (5 to 26) 1·13 (1·01 to 1·27)† 0·037
Initial reduction of severity of symptoms 662/786 (84%) 650/797 (82%) ·· ··
Time to initial reduction of severity of symptoms, days 7 (3 to 14) 8 (3 to 20) 1·19 (1·07 to 1·32)† 0·0019
Illness severity rating (1 worst, 10 best), mean (SD) [n]
Day 7 7·0 (1·8) [747] 6·6 (1·9) [759] 0·33 (0·14 to 0·52)‡ 0·0001
Day 14 7·9 (1·7) [745] 7·5 (1·7) [763] 0·37 (0·17 to 0·57)‡ <0·0001
Day 21 8·4 (1·5) [623] 7·9 (1·6) [612] 0·38 (0·15 to 0·61)‡ 0·0001
Day 28 8·4 (1·5) [759] 8·2 (1·5) [772] 0·19 (–0·07 to 0·44)‡ 0·16
WHO-5 Well-Being Index, mean (SD) [n]
Day 14 42·5 (25·0) [713] 39·4 (24·4) [724] 2·97 (0·64 to 5·30)‡ 0·013
Day 28 54·6 (25·1) [713] 52·0 (24·8) [721] 2·36 (0·03 to 4·69)‡ 0·047
Self-reported contact with at least one health-care service 416/778 (54%) 466/787 (59%) 0·90 (0·83 to 0·98)* 0·017
General practioner reported contact with at least one health-care service 305/602 (51%) 351/607 (58%) 0·87 (0·79 to 0·97)* 0·010
New infections in household 197/772 (26%) 214/782 (27%) 0·93 (0·79 to 1·10)* 0·40
Prescription of antibiotics 42/550 (8%) 53/543 (10%) 0·78 (0·53 to 1·15)* 0·24
Hospital assessment without admission 22/786 (3%) 22/797 (3%) 1·01 (0·57 to 1·82)* >0·99
Oxygen administration 50/774 (7%) 73/785 (9%) 0·69 (0·49 to 0·98)* 0·039
Mechanical ventilation 13/776 (2%) 14/784 (2%) 0·94 (0·44 to 1·98)§ >0·99
Intensive care unit admission 10/771 (1%) 21/779 (3%) 0·48 (0·23 to 1·01)§ 0·068
Duration of hospital admission, days, median (IQR) [n] 9·5 (5 to 28) [70] 10 (4 to 29) [95] –0·70 (–6·34 to 4·94)¶ 0·81
WHO ordinal scale of clinical progression
Not admitted to hospital 715/787 (91%) 701/799 (88%) 0·73 (0·53 to 1·01)|| 0·056
Admitted to hospital without need for supplemental oxygen 17/787 (2%) 21/799 (3%) ·· ··
Admitted to hospital with need for supplemental oxygen 36/787 (5%) 56/799 (7%) ·· ··
Admitted to hospital with need for non-invasive positive pressure 
ventilation or high-flow nasal cannula
0/787 1/799 (<1%) ·· ··
Admitted to hospital with need for mechanical ventilation or 
extracorporeal membrane oxygenation
13/787 (2%) 10/799 (1%) ·· ··
Death 6/787 (1%) 10/799 (1%) ·· ··
Data are n/N (%) or median (IQR) unless otherwise stated. Patients with data not available were not included in analyses. *Relative risks adjusted for age, comorbidity at 
baseline, duration of illness, and vaccination status at baseline. †Estimated hazard ratio derived from a Cox proportional hazard model adjusted for age, comorbidity at 
baseline, duration of illness, and vaccination status at baseline, with 95% CI. ‡Mixed-effects model adjusting for age, comorbidity, duration of illness, vaccination status 
at baseline, and time; participant was fitted as a random effect; WHO-5 score was also adjusted for the score at baseline. §Unadjusted relative risks due to low event rate. 
¶Adjusted difference in medians derived from quantile regression adjusted for age, comorbidity at baseline, duration of illness, and vaccination status at baseline. 
||Proportional odds ratio derived from ordinal logistic regression adjusted for age, comorbidity at baseline, duration of illness, and vaccination status at baseline.
Table 3: Secondary outcomes
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threshold (table 2). The treatment effect was consistent in 
the concurrent randomisation and overall study 
population (table 2, figure 2B).
In the primary analysis population, 72 (9%) of 
787 participants were admitted to hospital or died due to 
COVID-19 in the inhaled budesonide group (71 hospital 
admissions, of whom five died, and one death without 
hospital admission) compared with 116 (11%) of 1069 in 
the usual care group (114 hospital admissions, of whom 
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Figure 3: Forest plot of subgroup analysis of time to first reported recovery (A) and COVID-19-related hospital admission or death (B) in the concurrent 
randomisation and budesonide-eligible SARS-CoV-2-positive population
COPD=chronic obstructive pulmonary disease. *Not prespecified.
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In the Bayesian primary analysis model comparing 
hospital admissions or death between the budesonide 
group and usual care group, the odds ratio was 0·75 
(95% BCI 0·55 to 1·03), with an estimated rate of 6·8% 
(95% BCI 4·1 to 10·2) versus 8·8% (5·5 to 12·7), and an 
estimated absolute percentage difference of 2·0% 
(95% BCI –0·2 to 4·5; table 2). The probability of 
superiority was 0·963, which was below the predefined 
superiority threshold of 0·975. Results were similar in 
the con current randomisation population (probability of 
superiority 0·975) and the overall study population 
(probability of superiority 0·953; table 2).
Analysis of secondary outcomes (table 3), using the 
concurrent randomisation and eligible SARS-CoV-2-
positive population (787 in the budesonide group and 
799 in the usual care group), showed evidence of a 
benefit with budesonide in early sustained recovery, the 
daily illness severity rating over 28 days (appendix p 231), 
the WHO-5 Well-Being Index, health-care service use, 
oxygen administration, time to sustained recovery 
(appendix p 232), time to sustained alleviation of all 
symptoms (appendix p 233), and time to reduction of 
symptom severity (appendix p 234). There was no clear 
evidence of benefit for any other secondary outcomes.
In the prespecified subgroup analyses, there was no 
evidence that symptom duration before randomisation, 
baseline symptom severity score, age, or comorbidity 
modified the effect of budesonide on time to first reported 
recovery or hospital admission or death (figure 3). In 
post-hoc subgroup analyses, there was no evidence that 
the effect of budesonide differed by vaccination status or 
chronic lung disease status (figure 3), although numbers 
were small, particularly for chronic lung disease because 
those already using inhaled corticosteroids were ineligible 
for randomisation to budesonide. Regarding serious 
adverse events, there were two hospital admissions 
unrelated to COVID-19 in the budesonide group and four 
in the usual care group (appendix p 241).
Discussion
This analysis from a platform, randomised trial involving 
people in the community with COVID-19 at increased 
risk of an adverse outcome, found that participants using 
inhaled budesonide recovered an estimated 2·94 days 
sooner, had a greater sense of wellbeing while recovering, 
and once recovered, more often remained well (sustained 
recovery). The budesonide group did not meet the 
prespecified superiority threshold for the COVID-19-
related hospital admission or death outcome before data 
cutoff, but this might have been due to the rapid decrease 
in rate of hospital admissions or deaths in March and 
April, 2021, in the UK, because of the vaccination 
programme and lockdown measures. Overall, the 
consistency of these findings across both primary and 
secondary endpoints provides the strongest evidence 
thus far of an effective, safe, cheap, and readily available 
treatment for COVID-19 in the community.
PRINCIPLE is the largest randomised trial thus far to 
assess inhaled budesonide for community treatment of 
COVID-19. Our results are consistent with the STOIC 
phase 2 trial of 146 adults, in which inhaled budesonide 
reduced COVID-19-related emergency assessments or 
hospital admissions, compared with usual care, and self-
reported recovery favoured budesonide by 1 day.13 Several 
randomised trials have shown that systemic cortico-
steroids reduce mortality among people admitted to 
hospital with COVID-19,8,9 with the RECOVERY trial 
finding greatest benefit in mechanically ventilated 
patients, with no benefit or possibly harm in patients 
admitted to hospital not requiring oxygen.8
The pragmatic design of the PRINCIPLE trial allowed 
for efficient analysis of the effectiveness of budesonide as 
an early, standalone intervention as it might be used in 
the community. We focused on patients at increased risk 
of complications, explaining the higher proportion who 
were admitted to hospital than in other community 
COVID-19 trials.24,27 We used routine electronic health 
records to confirm hospital admission or death, and 
obtained primary outcome data on more than 95% of 
participants. We did secondary analyses of the coprimary 
outcomes in patients with suspected COVID-19 but 
without PCR-confirmed SARS-CoV-2 infection, because 
this reflects community testing conditions early in 
the UK pandemic, and low availability of SARS-CoV-2 
testing might necessitate early empirical treatment in 
other community and low-resource settings. Further-
more, variation in PCR testing sensitivity, particularly 
when the test is self-administered, means that some 
participants will have had false negative tests.28 Primary 
outcome estimates were similar in the SARS-CoV-2-
positive population, all participants irrespective of 
SARS-CoV-2 status, and the concurrent randomisation 
SARS-CoV-2-positive population.
Similar to other large COVID-19 platform trials,8,29 we 
used a pragmatic, open-label design because we aimed to 
assess the addition of budesonide to usual care, rather 
than to assess benefit of budesonide compared with a 
placebo. Our study therefore answers a question that is 
immediately relevant to policy makers—what would be 
the effect, compared with usual care, of introducing 
inhaled budesonide for community treatment of 
COVID-19? However, inhalers have been documented to 
have placebo effects in chronic respiratory conditions, 
which could have affected our self-reported time-to-
recovery outcome. We used this outcome because it was 
of greatest interest to our patient and public contributors 
and is best ascertained by direct patient report, rather 
than by surrogate measures. We found no evidence of a 
placebo effect in analyses of other (pill) treatments in this 
trial platform,15,16 and the hospital admissions or deaths 
outcome is less likely to be influenced by placebo effects.
This trial has provided evidence of a safe and cheap 
community treatment for COVID-19 that reduces 
symptom burden and enhances sustained recovery over 
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28 days, with a high probability of also reducing the 
need for hospital admission, albeit just below the 
prespecified superiority threshold in the primary analysis 
population. With ongoing, severe COVID-19 surges 
occurring globally, the need for effective, accessible 
treatments in the community that can reduce illness 
duration and prevent overburdening of hospitals and 
health-care services remains an urgent global priority. 
Inhaled budesonide is available in many primary care 
settings and is included in the WHO list of essential 
medicines.30 Further work is needed to establish how 
budesonide affects COVID-19 pathophysiology, the 
effectiveness of other inhaled corticosteroids, and the 
effect on so-called long COVID. A small proportion of 
our study population had received a SARS-CoV-2 vaccine. 
Although we found no evidence of a difference in the 
effect of budesonide by vaccination status, this analysis 
was probably underpowered. Further work is needed to 
establish the effect of budesonide among fully vaccinated 
people with COVID-19.
Our study provides evidence that inhaled budesonide 
is an effective and safe treatment for people with 
COVID-19 in the community who are at increased risk of 
adverse outcomes.
Contributors
CCB and FDRH decided to publish the paper. MB, PJB, REKR, DVN, DR, 
MIA, and SR contributed to the development of the intervention-specific 
appendix for inhaled budesonide. BRS, NB, L-MY, CCB, FDRH, GH, MS, 
OVH, OG, JD, and DR contributed to trial design. SdL, PHE, NPBT, and 
MGP helped plan the trial and ongoing recruitment. EO, NPBT, and 
SdL were responsible for acquisition of data. CCB, L-MY, JD, BRS, MB, 
FDRH, GH, OVH, and OG drafted the manuscript. BRS, NB, L-MY, 
MAD, MF, CS, VH, and MS contributed to the statistical analysis. 
All authors critically revised the manuscript. The members of the 
PRINCIPLE Trial Collaborative Group and their roles in the conduct of 
the trial are listed in the appendix (p 2). All authors had full access to all of 
the data in the study and take final responsibility for the decision to 
submit for publication. MS and VH accessed and verified the underlying 
data.
Declaration of interests
MB reports grants from AstraZeneca, personal fees from AstraZeneca, 
Chiesi, and GlaxoSmithKline; and is a member of advisory boards for 
Albus Health and ProAxsis, outside the submitted work. DR reports 
being a former employee of GlaxoSmithKline, outside the submitted 
work. BRS, NB, MAD, MF, and CS report grants from The University of 
Oxford, for the University of Oxford’s grant from the UK National 
Institute for Health Research (NIHR) and for statistical design and 
analyses for the PRINCIPLE trial during the conduct of the study. SdL is 
Director of the Oxford–Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre and reports that through his university 
he has had grants outside the submitted work from AstraZeneca, 
GlaxoSmithKline, Sanofi, Seqirus, and Takeda for vaccine-related 
research, and membership of advisory boards for AstraZeneca, Sanofi, 
and Seqirus. MIA reports grants and personal fees from Prenetics 
outside the submitted work. PJB reports grants and personal fees from 
AstraZeneca and Boehringer Ingelheim; and personal fees from Teva 
and Covis, during the conduct of the study. REKR reports grants from 
AstraZeneca and personal fees from Boehringer Ingelheim, Chiesi UK, 
and GlaxoSmithKline, during the conduct of the study. SR reports grants 
and non-financial support from Oxford respiratory NIHR Biomedical 
Research Centre (BRC), during the conduct of the study; and 
non-financial support from AstraZeneca and personal fees from the 
Australian Government Research Training Program, outside the 
submitted work. FDRH and CCB report grants from UK Research and 
Innovation, during the conduct of the study. All other authors declare no 
competing interests.
Data sharing
Data can be shared with qualifying researchers who submit a proposal 
with a valuable research question as assessed by a committee formed 
from the trial management group, including senior statistical and 
clinical representation. A contract should be signed.
Acknowledgments
We thank the patients who participated in this study. We also thank the 
many health and social care professionals who contributed. 
The PRINCIPLE trial platform is led from the Primary Care and Vaccines 
Collaborative Clinical Trials Unit at the University of Oxford’s Nuffield 
Department of Primary Care Health Sciences. PRINCIPLE is supported 
by a large network of care homes, pharmacies, NHS 111 hubs, hospitals, 
and 1401 general practices across England, Wales, Scotland, and Northern 
Ireland. The trial is integrated with the Oxford–RCGP Research and 
Surveillance Centre ORCHID digital platform. PRINCIPLE has been 
supported by the NIHR and its Clinical Research Network, 
NHS DigiTrials, Public Health England, Health and Care Research 
Wales, NHS Research Scotland, the Health and Social Care Board in 
Northern Ireland, and the Therapeutics Task Force. CCB acknowledges 
part support as Senior Investigator of the NIHR, the NIHR Community 
Healthcare Medtech and In-Vitro Diagnostics Co-operative (MIC), and 
the NIHR Health Protection Research Unit on Health Care Associated 
Infections and Antimicrobial Resistance, and was a part-time salaried 
general practitioner for the Cwm Taf Morgannwg University Health 
Board. FDRH acknowledges his part support as an NIHR Senior 
Investigator, as Director, NIHR Applied Research Collaboration Oxford 
Thames Valley, as Theme Lead, NIHR Oxford BRC (University Hospitals 
Trust), and the NIHR Community Healthcare MIC. JD and OG are 
funded by the Wellcome Trust PhD Programme for Primary Care 
Clinicians (216421/Z/19/Z to JD and 203921/Z/16/Z to OG). GH is 
funded by an NIHR Advanced Fellowship and by the NIHR Community 
Healthcare MIC. The PRINCIPLE trial is funded by a grant to the 
University of Oxford from UK Research and Innovation and the 
Department of Health and Social Care through the NIHR as part of 
the UK Government’s rapid research response fund. Pulmicort 
Turbohalers were purchased at cost. The views expressed are those of the 
authors and not necessarily those of the NIHR or the Department of 
Health and Social Care. The authors vouch for the accuracy and 
completeness of the data and for fidelity to the protocol.
References
1 Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical 
need. JAMA 2020; 324: 2149–50.
2 Nicolau DV, Bafadhel M. Inhaled corticosteroids in virus pandemics: 
a treatment for COVID-19? Lancet Respir Med 2020; 8: 846–47.
3 Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic 
respiratory diseases or their treatment affect the risk of SARS-CoV-2 
infection? Lancet Respir Med 2020; 8: 436–38.
4 Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids 
downregulate the SARS-CoV-2 receptor ACE2 in COPD through 
suppression of type I interferon. J Allergy Clin Immunol 2021; 
147: 510–19.e5.
5 Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in 
sputum cells in asthma. Relationship to demographic features and 
corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90.
6 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell 
entry depends on ACE2 and TMPRSS2 and is blocked by a clinically 
proven protease inhibitor. Cell 2020; 181: 271–80.e8.
7 Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid 
ciclesonide blocks SARS-CoV-2 RNA replication by targeting the 
viral replication-transcription complex in cultured cells. J Virol 
2020; 95: e01648-20.
8 Horby P, Lim WS, Emberson JR, et al. Dexamethasone in 
hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704.
9 WHO Rapid Evidence Appraisal for COVID-19 Therapies Working 
Group, Sterne JAC, Murthy S, et al. Association between 
administration of systemic corticosteroids and mortality among 
critically ill patients with COVID-19: a meta-analysis. JAMA 2020; 
324: 1330–41.
Articles
www.thelancet.com   Published online August 10, 2021   https://doi.org/10.1016/S0140-6736(21)01744-X 13
10 Welte T. SARS-CoV-2-triggered immune reaction: for COVID-19, 
nothing is as old as yesterday’s knowledge. Am J Respir Crit Care Med 
2021; 203: 156.
11 Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related 
death among patients with chronic obstructive pulmonary disease 
or asthma prescribed inhaled corticosteroids: an observational 
cohort study using the OpenSAFELY platform. Lancet Respir Med 
2020; 8: 1106–20.
12 Aveyard P, Gao M, Lindson N, et al. Association between pre-existing 
respiratory disease and its treatment, and severe COVID-19: 
a population cohort study. Lancet Respir Med 2021; published online 
April 1. https://doi.org/10.1016/S2213-2600(21)00095-3.
13 Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled 
budesonide in the treatment of early COVID-19 (STOIC): a phase 2, 
open-label, randomised controlled trial. Lancet Respir Med 2021; 
9: 763–72.
14 Woodcock J, LaVange LM. Master protocols to study multiple 
therapies, multiple diseases, or both. N Engl J Med 2017; 377: 62–70.
15 Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community 
treatment of suspected COVID-19 in people at increased risk of an 
adverse clinical course in the UK (PRINCIPLE): a randomised, 
controlled, open-label, adaptive platform trial. Lancet 2021; 
397: 1063–74.
16 Butler CC, Yu L-M, Dorward J, et al. Doxycycline for community 
treatment of suspected COVID-19 in people at high risk of adverse 
outcomes in the UK (PRINCIPLE): a randomised, controlled, 
open-label, adaptive platform trial. Lancet Respir Med 2021; 
published online July 27. https://doi.org/10.1016/
S2213-2600(21)00310-6.
17 Public Health England. COVID-19: investigation and initial clinical 




infection (accessed Jan 28, 2021).
18 UK National Health Service. Symptoms of coronavirus (COVID-19). 
2021. https://www.nhs.uk/conditions/coronavirus-covid-19/
symptoms/ (accessed Jan 28, 2021).
19 Patel MG, Dorward J, Yu L-M, Hobbs FR, Butler CC. Inclusion and 
diversity in the PRINCIPLE trial. Lancet 2021; 397: 2251–52.
20 National Institute for Health and Care Excellence. COVID-19 rapid 
guideline: managing symptoms (including at the end of life) in the 
community. April 3, 2020. https://www.ncbi.nlm.nih.gov/books/
NBK566885/ (accessed Aug 4, 2021).
21 National Institute for Health and Care Excellence. COVID-19 rapid 
guideline: managing suspected or confirmed pneumonia in adults 
in the community. April 3, 2020. https://www.ncbi.nlm.nih.gov/
books/NBK566869/ (accessed Aug 4, 2021).
22 UK Government. Coronavirus (COVID-19) in the UK. 
February 12, 2021. 2020. https://coronavirus.data.gov.uk/ (accessed 
July 13, 2021).
23 Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of 
coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 
2020; 20: 669–77.
24 Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in 
nonhospitalized adults with early COVID-19 : a randomized trial. 
Ann Intern Med 2020; 173: 623–31.
25 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the 
treatment of Covid-19—final report. N Engl J Med 2020; 
383: 1813–26.
26 Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 
Well-Being Index: a systematic review of the literature. 
Psychother Psychosom 2015; 84: 167–76.
27 Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Efficacy of colchicine in 
non-hospitalized patients with COVID-19. medRxiv 2021; published 
online Jan 27. https://doi.org/10.1101/2021.01.26.21250494 (preprint).
28 Woloshin S, Patel N, Kesselheim AS. False negative tests for 
SARS-CoV-2 infection - challenges and implications. N Engl J Med 
2020; 383: e38.
29 Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor 
antagonists in critically ill patients with Covid-19. N Engl J Med 
2021; 384: 1491–502.
30 WHO. WHO model list of essential medicines, 21st list, 2019. 
July 23, 2019. https://www.who.int/publications/i/item/
WHOMVPEMPIAU2019.06 (accessed March 19, 2021).
